Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 135

Similar articles for PubMed (Select 17484889)

1.

Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis.

Michalski CW, Laukert T, Sauliunaite D, Pacher P, Bergmann F, Agarwal N, Su Y, Giese T, Giese NA, Bátkai S, Friess H, Kuner R.

Gastroenterology. 2007 May;132(5):1968-78. Epub 2007 Feb 21.

2.

Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms.

Michler T, Storr M, Kramer J, Ochs S, Malo A, Reu S, Göke B, Schäfer C.

Am J Physiol Gastrointest Liver Physiol. 2013 Jan 15;304(2):G181-92. doi: 10.1152/ajpgi.00133.2012. Epub 2012 Nov 8.

3.

Cannabinoids in pancreatic cancer: correlation with survival and pain.

Michalski CW, Oti FE, Erkan M, Sauliunaite D, Bergmann F, Pacher P, Batkai S, Müller MW, Giese NA, Friess H, Kleeff J.

Int J Cancer. 2008 Feb 15;122(4):742-50.

4.

Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.

Davis MP.

Expert Opin Investig Drugs. 2014 Aug;23(8):1123-40. doi: 10.1517/13543784.2014.918603. Epub 2014 May 16. Review.

PMID:
24836296
5.

Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.

Xu JJ, Diaz P, Astruc-Diaz F, Craig S, Munoz E, Naguib M.

Anesth Analg. 2010 Jul;111(1):99-109. doi: 10.1213/ANE.0b013e3181e0cdaf. Epub 2010 Jun 3.

6.

The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.

Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL.

J Neurochem. 2007 Apr;101(1):87-98. Epub 2007 Jan 4.

7.

Cannabinoids in acute gastric damage and pancreatitis.

Dembiński A, Warzecha Z, Ceranowicz P, Dembiński M, Cieszkowski J, Pawlik WW, Konturek SJ, Tomaszewska R, Hładki W, Konturek PC.

J Physiol Pharmacol. 2006 Nov;57 Suppl 5:137-54.

8.

Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.

Sain NM, Liang A, Kane SA, Urban MO.

Neuropharmacology. 2009 Sep;57(3):235-41. doi: 10.1016/j.neuropharm.2009.06.004. Epub 2009 Jun 16.

PMID:
19538975
9.

Beneficial effects of cannabinoids (CB) in a murine model of allergen-induced airway inflammation: role of CB1/CB2 receptors.

Braun A, Engel T, Aguilar-Pimentel JA, Zimmer A, Jakob T, Behrendt H, Mempel M.

Immunobiology. 2011 Apr;216(4):466-76. doi: 10.1016/j.imbio.2010.09.004. Epub 2010 Sep 18.

PMID:
21056512
10.

Evaluation of selective cannabinoid CB(1) and CB(2) receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis.

Tambaro S, Casu MA, Mastinu A, Lazzari P.

Eur J Pharmacol. 2014 Apr 15;729:67-74. doi: 10.1016/j.ejphar.2014.02.013. Epub 2014 Feb 20.

PMID:
24561047
11.

Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice.

Izzo AA, Capasso R, Aviello G, Borrelli F, Romano B, Piscitelli F, Gallo L, Capasso F, Orlando P, Di Marzo V.

Br J Pharmacol. 2012 Jun;166(4):1444-60. doi: 10.1111/j.1476-5381.2012.01879.x.

12.

Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity.

Tepper MA, Zurier RB, Burstein SH.

Bioorg Med Chem. 2014 Jul 1;22(13):3245-51. doi: 10.1016/j.bmc.2014.04.062. Epub 2014 May 9.

PMID:
24856183
13.

Therapeutic potential of cannabinoid receptor ligands: current status.

Singh J, Budhiraja S.

Methods Find Exp Clin Pharmacol. 2006 Apr;28(3):177-83. Review.

PMID:
16810344
14.

Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML.

J Neurosci. 2005 Feb 23;25(8):1904-13.

15.

CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain.

Khasabova IA, Gielissen J, Chandiramani A, Harding-Rose C, Odeh DA, Simone DA, Seybold VS.

Behav Pharmacol. 2011 Sep;22(5-6):607-16. doi: 10.1097/FBP.0b013e3283474a6d.

16.

Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.

Svízenská I, Dubový P, Sulcová A.

Pharmacol Biochem Behav. 2008 Oct;90(4):501-11. doi: 10.1016/j.pbb.2008.05.010. Review.

PMID:
18584858
17.

The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects.

Kinsey SG, Mahadevan A, Zhao B, Sun H, Naidu PS, Razdan RK, Selley DE, Imad Damaj M, Lichtman AH.

Neuropharmacology. 2011 Feb-Mar;60(2-3):244-51. doi: 10.1016/j.neuropharm.2010.09.004. Epub 2010 Sep 16.

18.

Endocannabinoids are expressed in bone marrow stromal niches and play a role in interactions of hematopoietic stem and progenitor cells with the bone marrow microenvironment.

Jiang S, Zagozdzon R, Jorda MA, Parmar K, Fu Y, Williams JS, Wood JA, Makriyannis A, Banu N, Avraham S, Groopman JE, Avraham HK.

J Biol Chem. 2010 Nov 12;285(46):35471-8. doi: 10.1074/jbc.M110.144758. Epub 2010 Sep 7. Retraction in: J Biol Chem. 2011 Jul 8;286(27):24534.

19.

Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.

Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, Rabadi L, Rotshteyn Y, Chaffer SM, Turchin PI, Elsemore DA, Toth M, Koetzner L, Whiteside GT.

Neuropharmacology. 2005 Apr;48(5):658-72.

PMID:
15814101
20.

[The cannabinoid system and pain: towards new drugs?].

Beltramo M.

J Soc Biol. 2009;203(1):99-106. doi: 10.1051/jbio:2009002. Epub 2009 Apr 10. Review. French.

PMID:
19358815
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk